Status:
COMPLETED
Respiratory Physiotherapy Performed by Simeox In Patients With Primary Ciliary Dyskinesia
Lead Sponsor:
University Hospital, Motol
Conditions:
Primary Ciliary Dyskinesia
Eligibility:
All Genders
4-18 years
Phase:
NA
Brief Summary
Primary ciliary dyskinesia (PCD) is characterized by impaired airway clearance and mucus stagnation. This results in recurrent upper and lower respiratory tract infections often leading to chronic inf...
Detailed Description
In this study the effectiveness of ACT will be evaluated based on the short-term effect(s) of respiratory physiotherapy with Simeox on changes in lung function and thoracic expansibility paediatric pa...
Eligibility Criteria
Inclusion
- diagnosis of PCD confirmed by Transmission Electron Microscopy (TEM) analysis of ciliary ultrastructure showing clear structural axonemal defect and/or positive genetic testing for one (autosomal dominant) or two (autosomal recesive) PCD-causing mutations;
- age range 4 - 18 years;
- established chest physiotherapy with PARI O PEP
Exclusion
- inability to undergo the assessment and intervention
- noncompliance and/or nonadherence
Key Trial Info
Start Date :
July 15 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 28 2023
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04793724
Start Date
July 15 2019
End Date
February 28 2023
Last Update
March 2 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Motol University Hospital
Prague, Praha 5, Czechia, 150 06